据美国最近报道，通过监测患者的白细胞计数，能使与应用Sandoz的精神病药氯氮平（clozapine）相关的粒细胞缺乏症的危险性减少到1％以下。1990年被推出氯氮平，在调查研究后估计，这个潜在致命的不良反应在1％～2％的患者中发生，因而建立了对氯氮平的监测系统，如美国的氯氮 According to a recent U.S. report, the risk of agranulocytosis associated with Sandoz’s psychiatric drug clozapine can be reduced to under 1% by monitoring the patient’s white blood cell count. Clozapine was introduced in 1990 and after investigation it was estimated that this potentially fatal adverse event occurred in 1% to 2% of patients, thus establishing a monitoring system for clozapine, such as clozapine in the United States